Safety Shot, Inc. has submitted a response to the Securities and Exchange Commission (SEC) regarding comments on its Post-Effective Amendment No. 6 to Form S-1, initially filed on February 5, 2024. The response, dated February 9, 2024, addresses the SEC's inquiries from a comment letter dated February 8, 2024. Safety Shot has revised its Registration Statement to include details on allegations made by Bigger Capital Fund, L.P., and has added disclosures concerning the AEG (Coachella) lawsuit, which the company believes will be settled without material impact. Additionally, Safety Shot clarified the classification of its NoStingz product as a sunscreen, not a cosmetic, and provided further details on SS-100, which is characterized as a drug with potential for Orphan Drug Designation for treating Acute Alcohol Poisoning. The company has also updated its Government Regulation section to better explain the FDA approval process for drugs and the criteria for Orphan Drug Designation.

Safety Shot, Inc. has submitted a response to the Securities and Exchange Commission (SEC) regarding comments on its Post-Effective Amendment No. 6 to Form S-1, initially filed on February 5, 2024. The response, dated February 9, 2024, addresses the SEC's inquiries from a comment letter dated February 8, 2024. Safety Shot has revised its Registration Statement to include details on allegations made by Bigger Capital Fund, L.P., and has added disclosures concerning the AEG (Coachella) lawsuit, which the company believes will be settled without material impact. Additionally, Safety Shot clarified the classification of its NoStingz product as a sunscreen, not a cosmetic, and provided further details on SS-100, which is characterized as a drug with potential for Orphan Drug Designation for treating Acute Alcohol Poisoning. The company has also updated its Government Regulation section to better explain the FDA approval process for drugs and the criteria for Orphan Drug Designation.